We compared serum concentrations of infliximab with outcomes of 728 patients with moderately-to-severely active ulcerative colitis who participated in ACT-1 or ACT-2 ; efficacy data were collected at weeks 8 , 30 , and 54 ( for ACT-1 only ) .